Preliminary experience with tigecycline treatment for severe infection in children

Ye, Sheng; Zhang, Chenmei; Lin, Shupeng

doi:10.1007/s00431-018-3208-9

Cited by 12 publications

(30 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies on the efficacy of tigecycline in children are not prospective due to safety concerns but contain data from limited cases in which it was used as salvage therapy. [10][11][12][13][14] The FDA and European Medicines Agency have issued warnings regarding the use of tigecycline in children over 8 years of age. Acinetobacter species to carbapenem decreased to 6.2% from 2010 to 2017, and that to tigecycline was >80%.…”

Section: Discussionmentioning

confidence: 99%

“…It is seen that the use of tigecycline in children is generally preferred in severe infections such as bloodstream infection, meningitis, intraabdominal infection, and nosocomial pneumonia. 7,[12][13][14] In our study, tigecycline was generally used for indications such as sepsis, febrile neutropenia, and skin and soft tissue infections.…”

Section: Discussionmentioning

confidence: 99%

“…Paediatric patients who received tigecycline for at least 2 days (at least four doses) were analysed. [10][11][12][13][14]…”

Section: Study Participantsmentioning

confidence: 99%

“…However, tigecycline can be used as a salvage treatment in children when options are limited. [9][10][11][12][13][14][15] Because pharmacokinetic safety and efficacy data are not available for children, clinical trials are required to identify the most appropriate therapeutic strategies. We present our experience with the use of tigecycline in critically ill children to guide future studies.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Clinical and laboratory responses to tigecycline in children

Aslan

Kılıç

Kıral

et al. 2022

Clinical Pharmacy Therapeu

View full text Add to dashboard Cite

What is known and objective The frequency of multidrug‐resistant bacterial infections is increasing worldwide. Tigecycline may be an important option for children with life‐threatening nosocomial infections due to multidrug‐resistant bacteria. However, there are few published data on the use of tigecycline in paediatric patients. By examining the results of tigecycline use in children, we aimed to draw attention to the fact that tigecycline may be an alternative in the treatment of resistant infections in children. Methods Paediatric patients treated with tigecycline from 1 January 2010 to 31 October 2018 at Eskişehir Osmangazi University Medical Faculty, which is a tertiary hospital, were analysed retrospectively to assess the efficacy and safety of tigecycline treatment in children. Patients using tigecycline were identified using the pharmacy database. Clinical and laboratory data were obtained from the files. Results and discussion This study included 91 children aged 7 months to 17.5 years; 52 were female (57.1%). At least one predisposing factor was present in 98.9% of the patients. Fifty‐one bacteria were isolated from 44 patients. The tigecycline resistance rate was 3.9%. Only 2 of 91 patients experienced one or more side effects of tigecycline. Tigecycline can be used as salvage therapy in resistant infections where options are limited, although definitive conclusions about the efficacy and safety of tigecycline in children cannot be reached. What is new and conclusion Tigecycline may be a safe and important option in paediatric nosocomial infections due to resistant bacteria. Resistant bacterial infections have become more common in recent years, its treatment becomes a difficult problem. Tigecycline has a broad‐spectrum antibacterial activity including resistant pathogens.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

“…Paediatric patients who received tigecycline for at least 2 days (at least four doses) were analysed. [10][11][12][13][14]…”

Section: Study Participantsmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Clinical and laboratory responses to tigecycline in children

Aslan

Kılıç

Kıral

et al. 2022

Clinical Pharmacy Therapeu

View full text Add to dashboard Cite

show abstract

“…The patient in this case suffered from intolerable diarrhea leading to the discontinuation of tigecycline combination therapy. The result might also be attributed to other factors, such as a worse clinical condition and concomitant drugs ( 26 ). Therefore, additional data from controlled clinical studies are required to assess the safety of tigecycline, and particular caution should be given to off-label use of tigecycline, especially in pediatric patients.…”

Section: Discussionmentioning

confidence: 99%

Successful Treatment With Intrathecal and Intravenous Polymyxin B-Based Combination Against MDR Acinetobacter baumannii Meningitis in Pediatric Patient: A Case Report

et al. 2021

View full text Add to dashboard Cite

Background: Nosocomial meningitis with multidrug-resistant (MDR) or extensively drug-resistant (XDR) Acinetobacter baumannii is a life-threatening complication in neurosurgery. Treatment of these infections is challenging because of poor penetration of the available antibiotics into the cerebrospinal fluid (CSF). Intrathecal (ITH) or intraventricular (IVT) administration of antibiotics is increasingly used as the last treatment option against MDR/XDR Gram-negative bacteria meningitis not responding to intravenous (IV) regimens. However, pertinent data in pediatric patients is scarce.Case Presentation: A 14-year-old male patient developed meningitis from an MDR strain of A. baumannii following endoscopic endonasal resection of craniopharyngioma. Despite a combination therapy involving IV tigecycline, we observed clinical and bacteriologic failure. The patient was then successfully treated with an ITH and IV polymyxin B-based combination. Quantification of tigecycline and polymyxin B in CSF was performed with two-dimensional high-performance liquid chromatography (2D-HPLC) and HDLC coupled with tandem mass spectrometry (HPLC-MS/MS), respectively. Adverse drug reactions (neurotoxicity and skin hyperpigmentation), probably induced by polymyxin B, were acceptable and reversible.Conclusions: The case illustrates ITH and IV Polymyxin B-based combination is an optimal therapeutic option against MDR A. baumannii meningitis in this pediatric patient. In the future, real-time PK/PD data obtained from patients during ITH/IVT polymyxin B therapy should be required to optimize polymyxin use with maximal efficacy and minimal adverse effects.

show abstract

Tigecycline salvage therapy for ventriculoperitoneal shunt meningitis due to extensively drug-resistant Acinetobacter baumannii

Polat

Özkaya-Parlakay²

2018

Eur J Pediatr

View full text Add to dashboard Cite

Preliminary experience with tigecycline treatment for severe infection in children

Cited by 12 publications

References 24 publications

Clinical and laboratory responses to tigecycline in children

Clinical and laboratory responses to tigecycline in children

Successful Treatment With Intrathecal and Intravenous Polymyxin B-Based Combination Against MDR Acinetobacter baumannii Meningitis in Pediatric Patient: A Case Report

Tigecycline salvage therapy for ventriculoperitoneal shunt meningitis due to extensively drug-resistant Acinetobacter baumannii

Contact Info

Product

Resources

About